Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM178 (mirabegron) vs placebo and tolterodine in overactive bladder
2007-001451-19Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirabegron in overactive bladder (OAB) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Change in micturitions per 24 hours. Started Feb 2008; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2007-001451-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001451-19.